Summary
GlobalData, the industry analysis specialist's new report, "Major Depressive Disorder-Drug Pipeline Analysis and Market Forecasts to 2015" is an essential source of information and analysis on the global major depression market. The report identifies the key trends shaping and driving the global major depressive disorder market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global major depressive disorder sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData's team of industry experts.

Scope
The scope of the report includes:
-Annualized global major depressive disorder market revenues data from 2000 to 2008, forecast forward for 7 years to 2015.
-Geographies covered in this report include the US, the UK, Italy, Spain, Germany, France and Japan.  
-Pipeline analysis data providing a split across different phases by mechanism of action being developed and emerging trends. Key classes of mechanism of action include Selective Serotonin Reuptake Inhibitor (SSRI), Serotonin and Norepinephrine reuptake inhibitor (SNRI), Dopamine Antagonists, Neurokinin (NK) antagonists, NMDA, Triple reuptake inhibitor (serotonin, norepinephrine and dopamine) and Monoamine Oxidase (MAO)-A inhibitors. 
-Analysis of the current and future market competition in the global major depressive disorder market. Key market players covered are GlaxoSmithKline, AstraZeneca, H.Lundbeck, Pfizer, and Eli Lilly.
-Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
-Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for future market associated with major depressive disorder.

Reasons to buy
The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:
-Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
-Develop business strategies by understanding the trends shaping and driving the global major depressive disorder market.
-Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global major depressive disorder market in future.
-Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
-Identify emerging players with potentially strong product portfolio and create effective   counter-strategies to gain competitive advantage.
-Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
-What's the next big thing in the global major depressive disorder market landscape?-Identify, understand and capitalize

Table of Contents
1 Table of Contents
1 Table of Contents 3
1.1 List of Tables 5
1.2 List of Figures 5
2 Major Depressive Disorder Market: Market Characterization 6
2.1 Overview 6
2.2 Depressive Disorder Market Size 6
2.3 Depression Market Forecast and CAGR 7
2.4 Drivers and Barriers for the Major Depressive Disorder Market 8
2.4.1 Drivers for the Major Depressive Disorder Market 8
2.4.2 Barriers for the Major Depressive Disorder Market 8
2.5 Opportunity and Unmet Need 9
2.6 Key Takeaway 10
3 Major Depressive Disorder Market: Competitive Assessment 11
3.1 Overview 11
3.2 Strategic Competitor Assessment 11
3.3 Product Profile for the Major Marketed Products in the Major Depressive Disorder Market 12
3.3.1 Lexapro/Cipralex (Escitalopram oxalate) 12
3.3.2 Cymbalta (Duloxetine Hydrochloride) 12
3.3.3 Abilify (Aripiprazole) 13
3.3.4 Pristiq (Desvenlafaxine succinate) 14
3.3.5 Symbyax (Olanzapine and fluoxetine Hcl) 15
3.4 Key Takeaway 17
4 Major Depressive Disorder Market: Pipeline Assessment 18
4.1 Overview 18
4.2 Strategic Pipeline Assessment 18
4.2.1 Technology Trends Analytic Framework 18
4.3 Major Depressive Disorder Therapeutics-Promising Drugs under Clinical Development 19
4.4 Molecule Profile for Promising Drugs under Clinical Development 20
4.4.1 Vilazodone 20
4.4.2 Seroquel XR 21
4.4.3 LU AA21004 21
4.5 Major Depressive Disorder Therapeutics Market-Clinical Pipeline by Mechanism of Action 22
4.6 Major Depressive Disorder-Pipeline by Clinical Phases of Development 23
4.6.1 Major Depressive Disorder Therapeutics-Phase III Clinical Pipeline 23
4.6.2 Major Depressive Disorder Therapeutics-Phase II Clinical Pipeline 24
4.6.3 Major Depressive Disorder Therapeutics-Phase I Clinical Pipeline 26
4.7 Discontinued/Suspended Drugs for Major Depressive Disorder 27
4.8 Key Takeaway 27
5 Major Depressive Disorder Market: Implications for Future Market Competition 29
6 Major Depressive Disorder Market: Future Players in MDD Market 31
6.1 Introduction 31
6.2 GlaxoSmithKline plc. 31
6.2.1 Overview 31
6.2.2 CNS Portfolio 32
6.2.3 Major Depressive Disorder Product Portfolio 33
6.3 AstraZeneca 33
6.3.1 Overview 33
6.3.2 CNS Portfolio 34
6.3.3 Major Depressive Disorder Product Portfolio 35
6.4 H.Lundbeck A/S 35
6.4.1 Overview 35
6.4.2 CNS Portfolio 36
6.4.3 Major Depressive Disorder Product Portfolio 36
6.5 Pfizer Inc 37
6.5.1 Overview 37
6.5.2 CNS Portfolio 37
6.5.3 Major Depressive Disorder Product Portfolio 38
6.6 Eli Lilly and Company 39
6.6.1 Overview 39
6.6.2 CNS Portfolio 39
6.6.3 Major Depressive Disorder Product Portfolio 40
7 Major Depressive Disorder Market: Appendix 41
7.1 Market Definitions 41
7.2 Abbreviations 41
7.3 Research Methodology 42
7.3.1 Coverage 42
7.3.2 Secondary Research 43
7.3.3 Forecasting 43
7.3.4 Primary Research 46
7.3.5 Expert Panel validation 46
7.4 Contact Us 46
7.5 Disclaimer 46
7.6 Sources 46

List of Tables
1.1 List of Tables
Table 1: Global MDD, Panic and Anxiety Disorder Therapeutics Market, Revenue ($bn),  2000-2007 7
Table 2: Global MDD, Panic and Anxiety Disorder Therapeutics Market, Revenue ($bn),  2008-2015 7
Table 3: Major Marketed Products Comparison in the Major Depressive Disorder Market, 2009 16
Table 4: Major Depressive Disorder Therapeutics-Most Promising Drugs Under Clinical Development, 2009 19
Table 5: Major Depressive Disorder Therapeutics-Phase III Clinical Pipeline, 2009 23
Table 6: Major Depressive Disorder Therapeutics-Phase II Clinical Pipeline, 2009 24
Table 7: Major Depressive Disorder Therapeutics-Phase I Clinical Pipeline, 2009 26
Table 8: List of Discontinued Drugs for Major Depressive Disorder, 2009 27
Table 9: GlaxoSmithKline plc-CNS Marketed Products, 2009 32
Table 10: GlaxoSmithKline plc-CNS Pipeline Products, 2009 32
Table 11: AstraZeneca-CNS Marketed Products, 2009 34
Table 12: AstraZeneca-CNS Pipeline Products, 2009 34
Table 13: H.Lundbeck A/S-CNS Marketed Products, 2009 36
Table 14: H. Lundbeck A/S-CNS Pipeline Products, 2009 36
Table 15: Pfizer Inc-CNS Marketed Products, 2009 37
Table 16: Pfizer Inc-CNS Pipeline Products, 2009 38
Table 17: Eli Lilly and Company-CNS Marketed Products, 2009 39
Table 18: Eli Lilly and Company-CNS Pipeline Products, 2009 39

List of Figures
1.2 List of Figures
Figure 1: Global MDD, Panic and Anxiety Disorder Therapeutics Market  Revenue ($m) 2000-2015 7
Figure 2: Opportunity and Unmet Need, 2009 9
Figure 3: Strategic Competitor Assessment of the Major Marketed Products for MDD, 2009 11
Figure 4: Technology Trends Analytic Framework of the MDD Pipeline, 2009 18
Figure 5: Technology Trends Analytic Framework of the MDD Pipeline-Description, 2009 19
Figure 6: Major Depressive Disorder Therapeutics Market-Clinical Pipeline by Mechanism of Action,   2009 22
Figure 7: Major Depressive Disorder Pipeline by Phase of Clinical Development, 2009 23
Figure 8: Implications for Future Market Competition in the MDD Market, 2009 29
Figure 9: Major Depressive Disorder Therapeutics Market-Clinical Pipeline by Company, 2009 31
Figure 10: GlobalData Methodology 42
Figure 11: GlobalData Market Forecasting Model 45